Clinical trial
Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza…
NCT00377585 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00377585 |
|---|---|
| Title | Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population |
| Official title | A Phase II/III, Observer-blind, Multi-Country, Multi-Centre, Randomized Study to Demonstrate the Superiority in Terms of Immunogenicity of Adjuvanted Influenza Vaccine Administered in Adults Aged 50 Years and Older Compared to Fluarix™ |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Fluarix, adjuvanted influenza vaccine |
| Enrollment | 3,350 |
| Start date | Sep 22, 2006 |
| Completion | Jan 30, 2007 |
| First posted | Sep 18, 2006 |
| Last update posted | Apr 24, 2017 |
| Countries | Belgium, Germany, Norway, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: